Ascendia

  MARKET NEWS

IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
Gerresheimer Expands Technical Competence Center in Wackersdorf 
First Patient Enrolled in Investigator-Initiated Trial With OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema
KBio & ZERO Announce Exclusive Strategic Alliance to Develop a Globally Distributed & Rapidly Deployable Plant-Based Molecular Farming Network
IntelGenx Completes Enrollment for BUENA Montelukast VersaFilm Phase 2a Clinical Trial in Patients With Mild-to-Moderate Alzheimer’s Disease
SupplyOne Revolutionizes Medical & Pharmaceutical Packaging, Driving Down Costs & Enhancing Profitability

  FEATURED EDITORIAL

  COMPANY PROFILE

With more than 70 years’ experience in medical devices, Owen Mumford Pharmaceutical Services is a division of Owen Mumford, with the Head Office located in Woodstock, UK. Our global presence extends from manufacturing facilities in the UK and Malaysia to subsidiaries in the US, Germany, and France. Owen Mumford Pharmaceutical Services specialises in the design, development, and manufacture of injectable drug delivery systems for the pharmaceutical, biotech, and generics industries. Our trusted devices are used daily in the delivery of various medications for a multitude of conditions across the globe. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Sygnature Discovery Accelerates Global Growth With Major North American Acquisition

Sygnature Discovery Accelerates Global Growth With Major North American Acquisition

Leading integrated drug discovery partner, Sygnature Discovery, recently announced its acquisition of one of North America’s largest discovery Contract Research Organizations, Canada-based….

ProQR Therapeutics & Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen & Ultevursen Ophthalmic Assets

ProQR Therapeutics & Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen & Ultevursen Ophthalmic Assets

ProQR Therapeutics N.V. and Laboratoires Théa recently announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and….

Ocean Biomedical, Inc. Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day

Ocean Biomedical, Inc. Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day

On World Lung Cancer Day, Ocean Biomedical, Inc. is sharing details of its multi-pronged Lung Cancer Program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. He and his team have revealed that Chitinase 3-like-1 (CHi3L1) is a master regulator that inhibits….

Mitsubishi Gas Chemical Develops First-Ever, PFAS-Free Oxygen Absorber to Help the Industry Meet Emerging Global Regulations

Mitsubishi Gas Chemical Develops First-Ever, PFAS-Free Oxygen Absorber to Help the Industry Meet Emerging Global Regulations

In response to the growing legislation around per- and polyfluoroalkyl substances (PFAS), Mitsubishi Gas Chemical (MGC) has launched the first future-proof, eco-friendly packaging solution for the industry using a cleaner chemistry within record-breaking turnaround…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products

WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products

By: Jeffrey Tremain and Ania VanDyke, AbbVie Contract Manufacturing

Regulatory authorities now consider ophthalmic formulations designed for administration as eye drops to be drug-device combination products.The regulatory compliance requirements for such combination products are much more complex than those for

…

WHITEPAPER - Use of a Platform Formulation Technology to De-Risk Solid-State Variation in Drug Development

WHITEPAPER - Use of a Platform Formulation Technology to De-Risk Solid-State Variation in Drug Development

Active pharmaceutical ingredients (APIs) can exist in multiple crystal forms, known as polymorphs, that are chemically identical. Polymorphs of an API can appear over the course of development and lead to deviations across batches affecting stability, tableting properties, flowability, solubility, …

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

WHITEPAPER -  Long-Acting Injectable Nanoparticle Formulations

WHITEPAPER - Long-Acting Injectable Nanoparticle Formulations

Long acting injectable (LAI) formulations have been the subject of continued interest in the recent past due, in part, to their longer systemic circulation requiring less frequent dosing of drugs. Less frequent administration, as illustrated in Figure 1, make LAIs …

WHITEPAPER - Overcoming the Knowledge Gap: Long-Acting Injectables & Implantables

WHITEPAPER - Overcoming the Knowledge Gap: Long-Acting Injectables & Implantables

What’s In This Whitepaper?

Long-acting products, such as Long-Acting Injectables (LAIs) and implantables, have gained significant traction in recent years, revolutionizing patient treatment and medication adherence. By reducing the number of doses required, long-acting products improve patient compliance and eliminate …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 16 – Lyophilization Manufacturing
August 23 – Excipients